GENE JACOBS: Open Payments
NPI 1699743245 · CRANSTON, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,532 in 196 payments from 16 companies in 2025. Trend: 2023 $3,417 · 2024 $4,157 · 2025 $3,532
Food & beverage: $3,532
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $514 |
| Vanda Pharmaceuticals Inc. | 20 | $440 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $392 |
| Alkermes, Inc. | 13 | $384 |
| Neurocrine BioSciences, Inc. | 14 | $350 |
| Otsuka America Pharmaceutical, Inc. | 17 | $274 |
| E.R. Squibb & Sons, L.L.C. | 14 | $201 |
| Lundbeck LLC | 20 | $185 |
| Axsome Therapeutics, Inc. | 6 | $178 |
| Janssen Pharmaceuticals, Inc | 1 | $149 |
Products named: VRAYLAR, FANAPT, REXULTI, CAPLYTA, INGREZZA, LYBALVI, COBENFY, Auvelity.
Industry payments across RI — which companies pay providers there.
